Compare Adaptive Biotechnologies Corp (ADPT) vs Hewlett Packard Enterprise Co (HPE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Hewlett Packard Enterprise Co — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Hewlett Packard Enterprise Co trades at $44.53 (market cap $57.56B). The key difference: Hewlett Packard Enterprise Co is far larger — about 17.3× Adaptive Biotechnologies Corp's market cap, and Hewlett Packard Enterprise Co pays a 1.31% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | HPE | |
|---|---|---|
Market Cap | $3.33B | $57.56B |
Sector | Health | Technology |
52-Week High | $22.37 | $56.14 |
52-Week Low | $10.24 | $19.81 |
Enterprise Value | $3.19B | $73.52B |
Dividend Yield | — | 1.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
HPE trades at $43.445, up 5.42% today, with a bearish technical signal despite recent earnings beats. Revenue grew to $34.3B in 2025, but net income fell sharply to $57M, pressuring margins. Analysts show a mixed consensus with a $69.69 price target, implying significant upside. The stock faces headwinds from high valuation multiples and volatile cash flows, though AI server demand and dividend payments offer support.
The outlook balances growth from AI infrastructure investments against execution risks and margin pressure. Upside hinges on sustained earnings outperformance and debt management, while downside risks include competitive threats and macroeconomic volatility. Institutional sentiment is cautiously optimistic given the high price target disparity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →
